Drugs / hGH
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07260500 Comparator | Nov 2025 → Dec 2026 expected | fetal growth restriction | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07260500 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human growth hormone” NCT07260500 ↗ |
| Route | Subcutaneous | “Jintropin® dose 3, subcutaneous injection” NCT07260500 ↗ |